Pengfei Cui

机构：Beijing Technology and Business University, Chinese PLA General Hospital · ORCID：0000-0003-2143-664X

发表论文 45 篇 · 总被引 899 次 · h-index 17

代表论文

• Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis (2021 · Frontiers in Oncology · 被引 135)
• The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors (2021 · Clinical Medicine Insights Oncology · 被引 69)
• Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors (2020 · Journal of Hepatocellular Carcinoma · 被引 35)
• Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors (2021 · Translational Lung Cancer Research · 被引 31)
• Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis (2023 · Oncogene · 被引 23)
• Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma (2020 · Journal of Cancer Research and Clinical Oncology · 被引 23)